Product Description: Trovafloxacin mesylate is a broad-spectrum quinolone antibiotic with potent activity against Gram-positive, Gram-negative and anaerobic organisms. Trovafloxacin mesylate blocks the DNA gyrase and topoisomerase IV activity. Trovafloxacin mesylate is also a potent, selective and orally active pannexin 1 channel (PANX1) inhibitor with an IC50 of 4 μM for PANX1 inward current. Trovafloxacin mesylate does not inhibit connexin 43 gap junction or PANX2. Trovafloxacin mesylate leads to dysregulated fragmentation of apoptotic cells by inhibiting PANX1[1][2][3].
Applications: COVID-19-anti-virus
Formula: C21H19F3N4O6S
Citations: J Gen Physiol. 2025 Jan 6;157(1):e202413676./bioRxiv. 2024 Nov 06./Biotechnol Bioeng. 2021 Sep 3./Nat Neurosci. 2024 Jun 11.
References: [1]Giustarini G, et al. The hepatotoxic fluoroquinolone trovafloxacin disturbs TNF- and LPS-induced p65 nuclear translocation in vivo and in vitro. Toxicol Appl Pharmacol. 2020 Mar 15;391:114915./[2]Poon IK, et al. Unexpected link between an antibiotic, pannexin channels and apoptosis. Nature. 2014 Mar 20;507(7492):329-34./[3]Gootz TD, et al. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob Agents Chemother. 1996 Dec;40(12):2691-7.
CAS Number: 147059-75-4
Molecular Weight: 512.46
Compound Purity: 99.76
Research Area: Infection
Solubility: DMSO : 116.67 mg/mL (ultrasonic)/H2O : 20 mg/mL (ultrasonic)
Target: Antibiotic;Bacterial;Topoisomerase
Deutsch
English
